Assembly Biosciences exercises profit-share option for herpes program
Assembly Biosciences exercised a profit-sharing option under its collaboration with Gilead Sciences for a herpes treatment. It will share 40% of U.S. development costs and profits for the program.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.